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Abstract
The concentration of bone marrow (BM) aspirate (BMA) is increasingly valued for bone and cartilage repair, 
particularly with the rarity and donor-variability of BM-multipotential stromal cells (BM-MSCs). The present 
study aimed to assess BM-MSC yield following BM concentration using a fast and compact-sized vertical 
centrifugation system. BMA concentrate (BMAC) was separated in a 1 min process and collected easily 
after an automatic discarding of plasma and red blood cells. A significant increase in CD45low CD271high 
cells per BMAC volume (measured using flow-cytometry) was noted (4-fold, p = 0.0001). Additionally, 
the vertical centrifugation system helped to enrich colony numbers (assessed by CFU-F assays) in BMAC 
comparably with conventional centrifugation systems, BioCUE™ and SmartPReP-2® (4.3-fold, 4.6-fold and 
3-fold, respectively). Next, a functional assessment of BM-MSCs processed by vertical centrifugation was 
performed, and MSC viability and proliferation were not affected. Also, these BM-MSCs showed similar 
alkaline phosphatase and calcium levels to those of BMA-MSCs when osteogenically induced. Furthermore, 
glycosaminoglycans and Nile red levels in addition to the gene expression assays confirmed that there was 
no significant change in chondrogenic or adipogenic abilities between BMA-MSCs and BMAC-MSCs. The 
expression levels of selected angiogenic and immunomodulatory mediators were also similar between the 
two groups. Collectively, the vertical centrifugation system helped to enrich BM-MSCs effectively, while 
maintaining cell viability and functions. Thus, such a vertical centrifugation system for BM concentration 
can be valuable for various regenerative therapies.
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and quality control (Capelli et al., 2015). Therefore, 
BM concentration has become a popular approach 
within the practice of various regenerative therapies 
to enrich MSC quantities and growth factors helping 
bone and cartilage repair (Hernigou et al., 2005a; 
Hernigou et al., 2005b; Holton et al., 2016; Moatshe et 
al., 2017; Zhong et al., 2012). BMAC is considered to 
be clinically safe being from an autologous source and 
minimally manipulated (Gobbi et al., 2015; Moatshe 
et al., 2017; Song and Tuan, 2004). BMAC samples 
have been used for bone regenerative therapies in 
cases of complicated fracture healing such as delayed 
union, non-union, osteonecrosis (especially femoral 
head necrosis), osseous defects and bone lengthening 
(Babhulkar et al., 2017; Calori and Giannoudis, 2011; 
Giannoudis et al., 2013; Giannoudis et al., 2015; 
Imam et al., 2017; Kanakeshwar et al., 2017; Piuzzi et 
al., 2017). Additionally, implantation of BMAC has 
been reported to be a cellular therapy for repair of 
osteochondral defects, osteoarthritis-related cartilage 
damage or other chondral defects, mostly combined 
with supporting scaffolds (Adams et al., 2013; 
Coppens et al., 2018; Gessmann et al., 2012; Smyth et 
al., 2012).
 The most popular method to achieve BM 
concentration is the gradient density-based separation 
of BM components. This separation process involves 
centrifugation of BM samples and usually takes 15-
20 min followed by manual removal of the plasma 
layer and collection of the separated BMAC (or 
nucleated cells) layer. This process also involves 
using large-size centrifuges with a swinging 
horizontal bucket rotor and requires a centrifugation 
speed up to 1100 ×g (El-Jawhari et al., 2017). 
Heragen® maxx (Heraeus), a recently introduced 
BM concentration system, is based on vertical 
centrifugation. The vertical centrifugation accelerates 
gravity sedimentation in which a mixture of layers 
with different densities is allowed to be separated, 
so that the denser component moves radially and 
accumulates on the walls of the rotating bowl. In 
comparison to horizontal centrifugation methods, 
this vertical centrifugation system concentrates 
BM through higher-speed centrifugation, takes a 
very short time (i.e. 1 min) and is designed for an 
automatic discarding of plasma and RBCs (Douras et 
al., 2018). However, little is known about the effect of 
vertical centrifugation on BM-MSC enrichment and 
whether the fast and high-speed centrifugation has 
any damaging effect on the cell functions.
 The present study aimed to assess BM-MSC yield 
after vertical centrifugation of BMA when compared to 
those obtained using gradient density centrifugation. 
Secondly, the aim was to evaluate the viability and 
proliferation potential of freshly collected BMAC-
MSCs processed by vertical centrifugation when 
compared to unprocessed donor-matched MSCs 
in BMA samples. The culture-expanded BMAC-
derived MSCs were also assessed for differentiation 
potential and expression of soluble factors involved 
in angiogenesis and immunomodulation. This 
LEPR  leptin receptor
MACS  magnetic-activated cell sorting
MFI  mean fluorescence intensity
MSCs  multipotential stromal cells
PBS  phosphate-buffered saline
PRP  platelet-rich plasma
PGE2  prostaglandin E2
PPARG  peroxisome proliferator-activated
   receptor gamma
PRP  platelet-rich plasma
PTGES2 prostaglandin E synthase 2
RBC  red blood cell
RGB  red green blue
ROS  reactive oxygen species
SOX9  SRY-box 9
SPARC  osteonectin
SPP1  osteopontin
TGFβ  transforming growth factor beta
VEGF  vascular endothelial growth factor
WBC  white blood cell
Introduction
BMA as  a  s tandard source  of  MSCs has 
considerable potential for bone, cartilage and other 
musculoskeletal tissue  regenerative therapies (Gaul 
et al., 2019; Verboket et al., 2018). BM-MSCs were 
first experimentally described as fibroblast-like 
cells with plastic-adhesive, colony-forming and 
osteogenic capacities (Friedenstein, 1980). Uniquely, 
MSCs contribute to bone and other mesenchymal 
tissue repair either by direct differentiation (Zellner 
et al., 2014) or indirectly by the release of bioactive 
mediators that could have paracrine or autocrine 
activities (Baraniak and McDevitt, 2010; Caplan and 
Dennis, 2006; Pak et al., 2017). By these mediators, 
MSCs could support the survival and maturation of 
endothelial cells and help the formation of new blood 
vessels through the release of VEGF (Baraniak and 
McDevitt, 2010; Zwaginga and Doevendans, 2003). 
Additionally, MSCs produce immunomodulatory 
factors when stimulated by pro-inflammatory 
cytokines during the early healing phase (El-Jawhari 
et al., 2016). This immunomodulation to control 
inflammation is essential for the effective repair 
process, particularly osteogenesis (Hoff et al., 2011; 
Kovach et al., 2015; Lienau et al., 2010).
 BM-MSCs, whether detected as colony-forming 
cells or characterised by specific surface phenotype, 
e.g. as CD45low CD271high cells, are few in number and 
constitute less than 0.1 % of the total BM cells (Castro-
Malaspina et al., 1980; Cuthbert et al., 2012; El-Jawhari 
et al., 2017; Jones and McGonagle, 2008; Tormin et al., 
2011). Furthermore, the number of BM-MSCs varies 
significantly based on patient age and gender as well 
as between healthy individuals withing the same age 
range and gender (Cuthbert et al., 2012; El-Jawhari et 
al., 2017; Jones and Schafer, 2015; Siegel et al., 2013). 
In contrast, the culture expansion of BM-MSCs is 
a costly process with complicated steps for safety 
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knowledge could be valuable for further development 
of BM concentration techniques and potentially for 
improving bone and cartilage regenerative therapies.
Materials and Methods
Patient samples
33 patients (14 males and 19 females; median age: 
40 years; range: 21-66 years) participated in the study. 
All patients had elective orthopaedic procedures at 
the Trauma and Orthopaedic unit of Leeds General 
Infirmary and provided informed written consent 
according to the ethical approval with NREC number: 
06/Q1206/127, National Research Ethics Committee 
Yorkshire & Humber-Leeds East. From each patient, 
60 mL of iliac crest BM sample was aspirated by 
P.V.G. and, then, mixed with anticoagulant citrate 
dextrose, as previously described (Cuthbert et al., 
2015; Hernigou et al., 2013). The samples were loaded 
into either Heragen maxx® (12 × 12 cm) (n = 15), 
BioCUE™ (43 × 37 × 23 cm, Zimmer-Biomet, Warsaw, 
IN, USA) (n = 14) or SmartPReP-2® (46 × 42 × 22 cm, 
Harvest-Tech, Hudson, NY, USA) (n = 4) for 1, 15 or 
14 min centrifugation, respectively. From each of the 
original BMA and the resulting BMAC samples, 1 mL 
paired samples (donor-matched) were collected into 
EDTA tubes and mixed few times to prevent clotting. 
These collected samples were transported to the 
laboratory for experimental processing and analysis 
within 1-2 h of the collection, as described below.
Processing of BM samples
The 1 mL BMA and BMAC samples collected by 
vertical centrifugation were divided into aliquots for 
several analytic purposes. 100 µL freshly collected 
samples were used for enumeration of MSCs by flow 
cytometry. Also, freshly collected BMA and BMAC 
samples were analysed for counting other BM cells 
(including RBCs, WBCs and platelets) using an 
automatic haemocytometer (Sysmex; Sysmex Ltd, 
Milton Keynes, UK). These samples were diluted 
1 : 10 before being processed using the Sysmex. 
Cell counts were normalised per 1 mL of BMA or 
BMAC. The remaining of BMA and BMAC samples 
were used for CFU-F assays, measuring ROS levels 
and culture-expansion. BM samples obtained by 
BioCUE™ or SmartPReP-2® were only processed for 
CFU-F assays as controls for colony counts.
Culture-expansion of MSCs
Paired BMA and BMAC samples were treated 
with RBC lysis buffer (90 g/L NH4Cl, 10 g/L KCl 
and 2 mL/L of 0.5 mol/L EDTA) and washed twice 
with PBS (Sigma-Aldrich). The processed cells 
were distributed in cultures as 2-3 × 106 cells/25 cm2 
culture flask (Corning). After 48 h, the medium 
containing cells in suspension was discarded. Then, 
plastic-adherent cells were maintained in cultures 
until 70-80 % confluency, then they were detached 
using trypsin, divided 1 : 4 and moved into new 
flasks (passaged). The medium used for culture-
expansion was StemMACS™ MSC Expansion 
Media (Miltenyi Biotec), supplemented with 1 : 100 
penicillin/streptomycin (Sigma-Aldrich). Cultures 
were maintained at 37 °C and 5 % CO2. The medium 
was half changed every 3-4 d, and cells were kept in 
cultures until passage 3. Culture-expanded MSCs 
were further processed for trilineage differentiation, 
gene expression assays and soluble mediators’ 
measurements.
CFU-F assay for counting and proliferation of BM-
MSCs
The CFU-F assay was used to enumerate colony-
forming cells (MSCs), as reported previously (El-
Jawhari et al., 2017). Equal volumes (200 µL) of paired 
BMA and BMAC samples were treated with RBC lysis 
buffer. Then, cells were seeded in 10 cm culture dish 
(Corning). Each seeded sample contained an average 
of 5.3 × 106 (1.2-7.4 × 106) and 21 × 106 (3-38 × 106) cells 
for BMA and BMAC, respectively. All cell cultures 
were maintained in StemMACS™ MSC Expansion 
Media (Miltenyi Biotec), supplemented with 1 : 100 
penicillin/streptomycin (Sigma-Aldrich), at 37 °C 
and 5 % CO2 for 14 d with half-medium changes 
twice weekly. For colony counting, the medium was 
removed and the colonies were fixed using 10 % 
formalin (Sigma-Aldrich). Then, methylene blue dye 
(Sigma-Aldrich) was used to visualise colonies. The 
colonies were counted, and the normalised count per 
1 mL of BMA or BMAC was calculated. For assessing 
the proliferative capacity of native MSCs, colonies 
were scanned and analysed using Image J software 
(NIH). The coloured RGB images of CFU-F colonies 
were analysed as binary 8-bit greyscale images and 
the colony integrated density was calculated as area 
× mean grey density value.
Flow cytometry for BM-MSC enumeration
The method described by El-Jawhari et al. (2017) 
for the rapid enumeration of BM-MSCs was used. 
Antibodies against CD271 (Miltenyi Biotec) and CD45 
(BD Biosciences), in addition to the live nucleated cell 
marker Vybrant® DyeCycle™ Ruby Stain (Thermo 
Fisher Scientific), were used as recommended by 
the manufacturers. These antibodies were added 
into unprocessed freshly collected donor-paired 
BMA and BMAC samples for 5 min in the dark 
at room temperature. The dilutions, volume of 
antibody/dye : volume of BMA/BMAC sample were 
40 µL : 100 µL for CD271, 40 µL : 100 µL for CD45 and 
1 µL : 100 µL for Vybrant® DyeCycle™ Ruby Stain. 
Data were acquired on Attune NxT Flow Cytometer 
(Thermo Fisher Scientific). The automated volumetric 
counts of CD45low CD271high cells were analysed using 
Attune NxT Flow Cytometer software. Cell counts 
were normalised per 1 mL of BMA or BMAC.
Measuring intracellular ROS levels in BM-MSCs
A flow-cytometry-based assay was applied to 
measure intracellular ROS levels in BM-MSCs using 
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a fluorogenic oxidative stress sensor, Green CellROX® 
Flow Cytometry Kit (Thermo Fisher Scientific), as 
per manufacturer’s instructions. After processing 
with RBC lysis buffer, the freshly collected BM cells 
were labelled using the surface marker antibodies 
against CD271 (Miltenyi Biotec) and CD45 (BD 
Biosciences). Cells were also stained with calcein 
violet dye (Thermo Fisher Scientific) to define live 
cells. FMO tube with all antibodies and markers 
except CellROX® was used to define the positivity 
of CellROX®. Data were acquired on BD™ LSRII 4 
laser flow cytometer and analysed using FACSDiva 
software (BD Biosciences).
MSC differentiation assays
The BMA and BMAC culture-expanded MSCs 
(passage 3) were used for the tri-lineage differentiation 
assays, as shown previously (El-Jawhari et al., 2019b; 
Fragkakis et al., 2018). BMA culture-expanded 
MSCs in the expansion growth medium were used 
as control, as these BMA cells were the original 
(standard) population and were not processed by 
concentration. For the osteogenic assays, MSCs were 
equally seeded (10,000 cells/well) in the osteogenic 
StemMACS™ OsteoDiff Media (Miltenyi Biotec) 
for 2 weeks before being tested for ALP expression 
using fast blue stain (Sigma-Aldrich). To visualise 
the calcium deposition after 3 weeks of osteogenic 
cultures, alizarin red S stain was used (Sigma-
Aldrich). Furthermore, the calcium levels were 
quantified using the colorimetric Calcium Liquid kit 
(Sentinel Diagnostics). Cultured MSCs were lysed 
in 1 mol/L HCl solution following good mixing, 
then kept at − 20 °C until calcium was measured. 
Absorbance was read at 600 nm wavelength using 
Multiskan® EX reader and Ascent™ software 
(Thermo Fisher Scientific). Measured calcium levels 
were normalised to the DNA quantities, which 
were tested using NanoDrop™ spectrophotometer 
(Thermo Fisher Scientific).
 For the chondrogenic assays, MSCs were equally 
distributed (200,000 cells/tube) in the chondrogenic 
StemMACS™ ChondroDiff Media (Miltenyi Biotec) in 
conical shaped tubes to grow as pellets (200,000 cells/
pellet). Following 3 weeks of culture, some cell 
pellets were cryo-fixed and sectioned before being 
stained for proteoglycans using toluidine blue O 
dye (Sigma-Aldrich). Other cell pellets were digested 
in papain solution (100 mmol/L sodium phosphate 
buffer supplemented with 5 mmol/L Na2EDTA, 
10 mmol/L L-cysteine and 100 mg papain in 100 mL 
of the prepared buffer, Sigma-Aldrich). Then, the 
levels of GAG were quantified in papain-lysed cell 
pellets using a Blyscan™ kit (Biocolor Life Sciences, 
Carrickfergus, County Antrim, Ireland).
 For the adipogenic assays, MSCs were equally 
distributed (50,000 cells/well) and cultured in the 
adipogenic StemMACS™ AdipoDiff Media (Miltenyi 
Biotec) in replicate culture-wells. Following 3 weeks 
of culture, some cultured wells were stained using 
oil red O (Sigma-Aldrich) for cellular triglycerides 
and lipids. Other cultured wells were processed for 
the quantitative fluorescent staining using Nile red 
(cellular lipid stain, Sigma-Aldrich) and DAPI (nuclei 
stain, Sigma-Aldrich). The Nile red/DAPI ratio was 
calculated to assess the Nile red levels normalised to 
cell counts. All images for differentiated cells were 
captured using an Eclipse E1000 light microscope 
(Nikon).
ELISA for soluble factors produced by MSCs
Culture-expanded BM-MSCs (passage 3) of 
paired BMA and BMAC samples were seeded 
equally (100,000 cells/well) in 12-well culture 
plates (Corning). Cells were cultured for 5 d in the 
StemMACS™ MSC Expansion Media. Then, culture 
supernatants (1 mL) were collected for analysis of 
soluble factors. ELISA kits for immunomodulatory 
factors, PGE2 and TGFβ, as well as for angiogenic 
factors, VEGFA and angiogenin, were used as per 
manufacturer’s recommendation (Thermo Fisher 
Scientific). Levels of the tested factors were measured 
using standard curves and normalised to cell count 
(measured as DNA quantity using the NanoDrop™ 
spectrophotometer).
Gene expression assays
Passage 3 culture-expanded MSCs (5-10 × 106 cells) 
from paired BMA and BMAC samples were processed 
for RNA extraction using a column-based kit (Single 
Cell RNA Purification Kit; Norgen, Thorold, 
Canada, ). cDNA synthesis and preamplification 
steps were conducted using which products? as per 
manufacturer’s instructions (Fluidigm, South San 
Francisco, CA, USA). Quantitative real-time PCR 
was performed on Integrated Fluidic Circuits chips 
(Fluidigm). TaqMan probes were used for tested gene 
targets (Thermo Fisher Scientific). Probes included 
SPP1 (Hs00959010_m1), BMP2 (HS00154192_m1), 
SPARC (Hs00277762_m1), ACAN (Hs00153936_m1), 
SOX9 (Hs00165814_m1), PPARG (Hs01115513_m1), 
LEPR (Hs00174492_m1), ANGP1 (Hs00181613_m1), 
VEGFA (Hs00900058_m1), TGFβ1 (Hs00998133_m1), 
PTGES2 (Hs00228159_m1) and the housekeeping gene 
HPRT1 (Hs99999909_m1). The relative expression of 
genes of interest was calculated using the formula: 
2− (Ct of a gene of interest - Ct of HPRT1) (El-Jawhari et al., 2019a).
Statistical analysis
Figure preparation and statistical analysis were 
performed using GraphPad Prism 7 software. Paired 
comparison tests were used for BMA and BMAC 
samples according to data normality distribution 




The vertical-centrifugation-based concentration 
of BMAs was performed as a part of a surgical 
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operation and required only 1 min centrifugation. The 
centrifugation resulted in a separation of three layers 
of plasma, buffy coat and the rest of BM cells including 
RBCs (Fig. 1a, step 1). An automatic discarding of 
other BM cells and RBCs, followed by the plasma 
layer, was conducted (Fig. 1a, step 2 and 3). Finally, 
the only remaining BMAC layer was collected using 
a syringe (Fig. 1a, step 4). The collected buffy coat of 
BMACs was 6 mL in all samples and only 1 mL was 
used for the laboratory assays. For the enumeration 
of the freshly collected MSCs, an optimised flow-
cytometry-based rapid assay was used (El-Jawhari et 
al., 2017). The flow cytometry plots showed that the 
numbers of CD45low CD271high cells, the surrogates of 
BM-MSCs, per mL of BMACs were increased when 
compared to those of donor-matched BMA samples 
(Fig. 1b). For all samples processed by vertical 
centrifugation, a significant increase in CD45low 
CD271high cell number/mL was noted for BMAC 
(p = 0.0001, Fig. 1c). The number of CD45low CD271high 
cells was donor-variable as expected (El-Jawhari et al., 
2017; Muschler et al., 2001) and ranged between 248 
and 62,300 cells (median 1,245 cells/mL) for BMA and 
1,605 and 140,000 cells (median 4,470 cells/mL) for 
BMAC samples. These data indicated a nearly 4-fold 
enrichment in CD45low CD271high cells in BMACs 
using the vertical centrifugation system.
 Both BMAC and BMA cells processed by vertical 
centrifugation were able to form colonies when 
seeded in culture but more colonies per volume were 
observed in the BMAC dishes (Fig. 1d). The number 
of colonies/mL of BMAC were consistently larger 
than those of donor-paired BMA samples (p = 0.0312, 
Fig. 1e). The number of colonies ranged between 5 
and 420 (median 63) for 1 mL of BMA samples and 20-
1,000 (median 270) for 1 mL of BMAC samples. These 
data showed a nearly 4.3-fold increase in colonies in 
BMACs when compared to the same volume of BMA 
samples.
 Age-matched comparison between vertical 
centrifugation and conventional BM concentration 
systems, BioCUE™ and SmartPReP-2® (median age 
of 37, 40 and 42 years old, respectively), was next 
performed. Similar to vertical centrifugation data, the 
colony numbers were increased significantly, 4.6-fold 
in BMACs using BioCUE™ (p = 0.0078) and 3-fold 
Fig. 1. Enumeration of MSCs in BMAC obtained using the vertical centrifugation system. (a) The vertical 
centrifugation of BMA, yielding a buffy coat of BMAC (as indicated by the arrow, step 1, 1 min), was followed 
by the removal of most other BM cells, including RBCs (step 2, few seconds), discarding of plasma (step 
3, few seconds) and collection of BMAC into a syringe (step 4). (b) Representative flow cytometry plots 
showing the gating of the CD45low CD271high cells in BMA and BMAC samples. (c) CD45low CD271high cell/
mL of donor-paired BMA and BMAC samples (n = 14). (d) Representative CFU-F culture dishes showing 
the colonies formed by paired BMA and BMAC samples and stained using methylene blue. (e) Number of 
colonies/mL of paired BMA and BMAC samples (n = 12). (f) Number of colonies/mL of BMA and BMAC 
using vertical centrifugation system (Heragen® maxx), BioCUE™ and SmartPReP-2® (n = 10, 14, and 4 
respectively). (c,e,f) * p < 0.05, Wilcoxon matched-pairs signed-rank test. 
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for SmartPReP-2® (p = 0.0156) (Fig. 1f). Furthermore, 
data showed that there was no significant difference 
between the average colony number/mL of BMAC 
obtained by the three concentration systems (Fig. 1f).
 The main advantage of the tested vertical 
centrifugation system was the 4-fold enrichment 
in BM-MSCs in a small volume. This enrichment 
was comparable to other tested systems for BM 
concentrations, but importantly with a reduction in 
processing time from 15-20 min to 1-2 min.
MSC concentration in relation to other BM cell 
numbers and donor-related factors
The effect of the vertical centrifugation on the 
numbers of other BM cells was investigated. Cells 
were counted using an automatic haematopoietic 
cell counter, Sysmex. Compared to BMA counts, the 
numbers of platelets and WBCs per mL of BMAC 
were significantly increased (7.6-fold, p = 0.0005 and 
3.7-fold, p = 0.001, respectively, Fig. 2a,b). In contrast, 
the number of RBCs per mL of BMAC was reduced 
Fig. 2. Various BMA cell counts and donor factors in relation to Heragen® maxx-enriched BM-MSCs. (a-c) 
Number of platelets, WBCs and RBCs in BMA as compared to BMAC obtained using vertical centrifugation 
(n = 10). (d-f) Fold increase in platelets, WBCs and RBCs versus colony fold increases in BMAC samples 
processed by vertical centrifugation. (g-i) Number of BMA platelets, WBCs and RBCs versus colony fold 
increase in BMAC samples processed by vertical centrifugation. (j) Colony fold increase in BMAC samples 
processed by vertical centrifugation in females versus males. (k) Donor age versus fold colony increase in 
BMAC samples processed by vertical centrifugation. * p < 0.05. (a-c) Wilcoxon matched-pairs signed-rank 
test was used for paired comparisons. (d-k) Spearman’s rho test was applied. 
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considerably as compared to that of BMA (25 % 
reduction, p = 0.0205, Fig. 2c). These data indicated an 
enrichment in platelets and WBCs as well as a loss of 
RBCs in BMAC processed by vertical centrifugation.
 Next, the relationships between the enrichment of 
BM-MSCs and changes in other BM cells following 
concentration were studied. Interestingly, the colony 
fold increases positively correlated with the fold 
increase of WBCs (p = 0.0415, Fig. 2e). However, the 
colony fold increases were not statistically correlated 
with the increases in platelets or the decreases in RBCs 
(Fig. 2d,f). With regards to the cell counts in BMA, 
the fold increases in colony numbers (enrichment) 
were significantly and positively correlated with the 
counts of platelets and RBCs in BMA (p = 0.0076 and 
p = 0.0245, respectively, Fig. 2g,i). Furthermore, there 
was a positive correlation trend between the colony 
fold increase (enrichment) and the number of WBCs 
in BMA, despite not being statistically significant (Fig. 
2h).
 Looking at other donor-related factors that might 
have influenced the enrichment of BM-MSCs, male 
and female donors had similar median levels of 
4-fold in colony fold increases (enrichment) (Fig. 
2j). Additionally, the donor age did not show any 
correlation with the fold increase in colony number 
(Fig. 2k).
 Taken together, another key advantage of BM 
concentration by vertical centrifugation appeared to 
be the enrichment of WBCs and platelets. No linkage 
to age or gender was observed.
Fig. 3. Survival, ROS levels and proliferation of BM-MSCs after using the vertical centrifugation system. 
(a) Flow cytometry gating on CD45low CD271high cells. Live cells were identified as calcein violet positive, 
followed by CellROX® MFI measurement in a test (black histogram) or Fluorescence Minus One Control FMO 
(grey histogram). (b) Percentage of live CD45low CD271high cells in BMA and BMAC samples. (c) CellROX® 
levels were measured in paired CD45low CD271high cells in BMA and BMAC samples (n = 9). (d) Scanned 
RGB colonies were analysed using image J software as binary image for integrated density. (e) Median of 
integrated density units between BMA and BMAC colonies (n = 5 donors, Mann-Whitney U test). (b,c,e) 
* p < 0.05, paired t-test was used for paired comparisons. 
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Fig. 4. Differentiation of culture-expanded BM-MSCs after vertical centrifugation processing. (a) Fast blue 
and alizarin red stainings for BMA- and BMAC-MSCs after culture in osteogenic medium for 2 weeks (for 
fast blue) or 3 weeks (for alizarin red). Control images for BMA-MSCs in expansion medium are shown. (b) 
Levels of calcium normalised to cell counts of BMA- and BMAC-MSCs maintained in osteogenic medium 
for 3 weeks (n = 5) and control BMA-MSCs (expansion, n = 5). * p < 0.05. (c) Relative gene expression levels 
of osteogenic markers (n = 4). Control: BMA-MSCs (day 0, n = 4). (d) Toluidine blue staining for BMA- and 
BMAC-MSC pellets maintained in chondrogenic medium for 3 weeks. A control image for BMA-MSC pellet 
in expansion medium is shown. (e) GAG levels in BMA- and BMAC-MSCs maintained in chondrogenic 
medium for 3 weeks (n = 5) and control BMA-MSCs (expansion, n = 5). * p < 0.05. (f) Relative gene expression 
levels of chondrogenic markers (n = 4). Control: BMA-MSCs (day 0, n = 4). (g) Oil red O staining for BMA- and 
BMAC-MSCs maintained in adipogenic medium for 3 weeks. A control image for BMA-MSCs in expansion 
medium is shown. (h) Nile red/DAPI ratios for BMA- and BMAC-MSCs maintained in adipogenic medium 
for 3 weeks (n = 5) and control BMA-MSCs (expansion, n = 4). * p < 0.05. (i) Relative gene expression levels 
of adipogenic markers (n = 4). Control: BMA-MSCs (day 0, n = 4). Wilcoxon matched-pairs signed-rank test 
was used for group comparisons except for (b) calcium levels, where paired t-test was used. 
MSCs processed by vertical centrifugation did 
not show an induction of intracellular ROS and 
maintained their survival and proliferative capacity
Quantity, stress status, survival and proliferation 
potential of MSCs following BM concentration 
by vertical centrifugation were assessed. By flow 
cytometry, the survival of CD45low CD271high cells 
was analysed using calcein violet dye (Fig. 3a). 
Then, these live cells were further analysed for 
intracellular ROS levels by measuring the MFI levels 
of CellROX® dye expression (Fig. 3a). The percentage 
of live CD45low CD271high cells was comparable for 
both BMA and BMAC samples (median of 96 % and 
95 %, respectively; Fig. 3b). Interestingly, the levels of 
intracellular ROS in BMAC samples were not induced 
but appeared to be lower than those of BMA samples 
(p = 0.0323, Fig. 3c).
 The colonies formed in BMA and BMAC 
cultures were analysed for their density to assess 
the proliferative potential of MSCs (Fig. 3d). Image 
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J semi-quantitative analysis showed that there was 
no significant difference in the colony integrated 
densities between donor-matched BMA and BMAC 
samples (p = 0.312, Fig. 3e), suggesting preservation 
of the proliferative capacity of MSCs.
 In summary, there was no significant difference in 
BMAC versus BMA fraction in terms of ROS induction 
using vertical centrifugation for BM concentration. 
Furthermore, the survival and proliferative capacities 
of BM-MSCs after processing were maintained.
MSCs processed by vertical centrifugation showed 
preserved tri-lineage differentiation potential
To assess the repair functions of MSCs processed 
by vertical centrifugation, culture-expanded BMA- 
and BMAC-MSCs were investigated using the 
mesenchymal lineage differentiation assays. The 
osteogenic cultures showed that both BMA- and 
BMAC-MSCs were positively stained when using 
fast blue more than expansion controls, indicating 
induction of ALP expression in differentiating 
MSCs (Fig. 4a, left panel). Furthermore, BMA- and 
BMAC-MSCs in osteogenic cultures were similarly 
positively stained for alizarin red, indicating effective 
deposition of calcium (Fig. 4a, right panel). Calcium 
quantitative measurement (normalised to cell counts) 
demonstrated a significant increase when compared 
to control (p = 0.0079) but comparable levels between 
the two populations, BMA- and BMAC-MSCs, with 
no statistically significant difference (p = 0.5919, 
Fig. 4b). These data were further confirmed by 
comparable gene expression levels of induced 
osteogenic markers (compared to control): SPP1, 
BMP2 and SPARC (p = 0.2656, p = 0.1484 and p > 0.999, 
respectively, Fig. 4c).
 After a 3 week culture in the chondrogenic 
medium, BMA and BMAC MSC pellets were 
positively stained with toluidine dye, differently 
from control MSCs in expansion medium, indicating 
successful chondrogenic differentiation (Fig. 4d). The 
quantitative levels of GAGs in BMA- and BMAC-
MSCs were found to be significantly higher than 
in the control (p = 0.0159) but to a similar extent 
in the two populations (median of 1.2 and 1 µg/
mL, respectively), with no significant difference 
(p = 0.8125, Fig. 4e). Furthermore, the gene expression 
levels of the chondrogenic markers ACAN and SOX9 
were higher in differentiating BMA- and BMAC-
MSCs than in control, but no significant difference 
was found between BMA and BMAC (p = 0.1641 and 
p = 0.7188, Fig. 4f).
 With regards to the adipogenic assay, both BMA- 
and BMAC-MSCs adipogenic cultures demonstrated 
red staining when using oil red O dye as compared 
to control cultures in expansion medium, suggesting 
the presence of lipid droplets (Fig. 4g). When these 
adipogenic induced MSCs were analysed for Nile red 
and DAPI fluorescence, the values of Nile red/DAPI 
ratio were also similar for differentiating BMA- and 
BMAC-MSCs (higer, relative to control, p = 0.0159), 
with no significant difference between the two 
populations (p = 0.9080, Fig. 4h). Additionally, the 
gene expression levels for the adipogenic markers 
PPARG and LEPR were comparable for both MSCs 
(p = 0.0625, p > 0.999, respectively, Fig. 4i).
 Collectively, analysis of trilineage potential 
showed no apparent differences between BMA and 
BMAC populations using the vertical centrifugation 
system, given the following results:
i) osteogenesis, comparable and no significant 
differences in gene expression levels for SPP1, BMP2 
and SPARC;
ii) chondrogenesis, comparable and no significant 
differences in gene expression levels for ACAN and 
SOX9;
iii) adipogenesis, comparable and no significant 
differences in gene expression levels for PPARG and 
LEPR.
MSCs processed by vertical centrifugation 
maintained angiogenic and immunomodulatory 
potential
Whether the soluble factors released by the BMAC-
MSCs were affected by the vertical centrifugation was 
tested. The culture supernatants from paired BMA 
and BMAC culture-expanded MSCs were analysed for 
levels of MSC-derived soluble factors involved in the 
immunomodulatory and vascular support activity. 
The levels of angiogenin and VEGFA in the culture 
supernatants with or without cell normalisation were 
similar for donor-paired BMA- and BMAC-MSCs, 
with no statistically significant difference (p = 0.7109 
and p = 0.9375, respectively, Fig. 5a). Furthermore, 
PGE2 and TGFβ-1 levels in the culture supernatants, 
with or without normalisation to cell counts, were 
similar for donor-paired BMA- and BMAC-MSCs 
(p = 0.1562 and p = 0.1484, respectively, Fig. 5b).
 To further confirm the similar levels of angiogenic 
and immunomodulatory soluble mediators, the 
gene expression levels of these markers were tested. 
Likewise, the transcripts for ANGP1 and VEGFA 
were comparable between BMA- and BMAC-
MSCs (p = 0.7109 for both, Fig. 5c). Also, there was 
no statistically significant difference in transcript 
expression levels of TGFβ-1 and PTGES2 between 
BMA- and BMAC-MSCs (p = 0.1484, and p = 0.7109, 
respectively, Fig. 5d).
 In summary, ANGP1 and VEGFA expression was 
not significantly different between BMA- and BMAC-
MSCs. Similarly, immunomodulatory potential was 
not significantly different between BMA- and BMAC-
MSCs, as similar expression levels of TGFβ-1 and 
PTGES2 were found.
Discussion
The present study uniquely tested a vertical 
centrifugation system, a fast and new technique 
for BM concentration. The main advantage of this 
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vertical centrifugation system was obtaining a 
4-fold enrichment in CFU-F colonies (MSCs) per 
volume of BMAC. Another advantage was the 
reduction of the typical centrifugation processing 
time from 15-20 min to 1-2 min, with the enrichment 
of WBCs and platelets. Additionally, the tri-
lineage multipotentiality, immunomodulatory and 
angiogenic properties examined for BMA- and 
BMAC-MSCs were equivalent, with no significant 
difference. The comparable and non-significant 
differences in properties between BMA- and 
BMAC-MSCs indicated that the high-speed vertical 
centrifugation was not detrimental to BMAC cell 
functions. Furthermore, as these cells were tested 
for differentiation and immunomodulatory potential 
after expansion, this also suggested their suitability 
for various therapeutic uses. In addition to the 
CFU-F assay, an optimised and published method 
was utilised to obtain BM-MSCs surrogates with 
surface phenotype CD45low CD271high (El-Jawhari 
et al., 2017), which specifically have significant 
osteogenic differentiation ability (Churchman et al., 
2012, Cuthbert et al., 2012). Both quantitative CFU-F 
and flow-cytometry methods showed a significant 
increase in MSC numbers (4-fold) per mL of BMAC 
relative to the same volume of BMA. Although the 
CFU-F assay is the standard method for BM-MSC 
counting, this assay cannot provide timely results 
as it requires several days in culture. The seeding 
for the CFU-F assay was performed based on equal 
volumes of the samples (BMA or BMAC). However, 
the numbers of colonies per volume were variable 
between donors as expected, probably related to age 
and gender, as reported before (El-Jawhari et al., 2017; 
Muschler et al., 2001). Therefore, the optimised flow 
cytometry method described in the present study 
(that takes up to 20 min) could potentially help to 
evaluate BMAC quality (MSC content) within intra-
operative clinical settings.
 The vertical centrifugation system for BM 
concentration also showed a comparable enrichment 
of MSCs (4-fold) with two other tested horizontal 
centrifugation systems, BioCUE™ (4.6-fold) and 
SmartPReP-2® (3-fold). Additionally, Emcyte 
Fig. 5. Soluble factors produced by vertical-centrifugation-processed BM-MSCs. (a) Total (pg/mL) 
or normalised to cell count levels of angiogenic mediators in the supernatants of culture-expanded 
MSCs derived from BMA and BMAC (n = 4). (b) Total (pg/mL) or normalised to cell count levels of 
immunomodulatory-related mediators in the supernatants of culture-expanded MSCs derived from BMA 
and BMAC (n = 4). (c) Relative gene expression levels of angiogenic mediators (n = 4). (d) Relative gene 
expression levels of immunomodulatory mediators (n = 4). Wilcoxon matched-pairs signed-rank test was 
used for group comparisons. 
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GenesisCS® (Emcyte, Fort Myers, FL, USA) and 
Harvest-Tech systems have been shown to enrich 
MSCs (as CD45low CD271high cells) significantly 
(Schafer et al., 2019), further confirming comparable 
performance for these systems. It was not feasible to 
get samples from the same donor for three systems 
and ideally to perform a paired comparison of 
BM-MSCs. However, an age-matched comparison 
was conducted between the tested systems and 
the colony enrichment were similar. Furthermore, 
both vertical and horizontal centrifugation systems 
helped to reduce RBCs and increase the number 
of platelets and WBCs per volume of BMAC. 
Horizontal centrifugation systems such as BioCUE™ 
and SmartPReP-2® need large-sized equipment (i.e. 
centrifuge) and usually need 15 min centrifugation 
time (El-Jawhari et al., 2017; Schafer et al., 2019). 
However, smaller centrifuge/device size and shorter 
centrifugation time (1 min) for the studied system 
suggested that vertical centrifugation could be a 
better tool for BM concentration. Additionally, the 
easy handling of the sample is another advantage 
of this system because the unused BM components 
(plasma and many RBCs) can be removed within 
seconds by pressing a button, leaving only BMAC 
buffy coat. Additionally, BMAC buffy coat can easily 
be extracted from the disposable device using a 
syringe.
 An enrichment in platelet and WBC counts was 
detected (7.6- and 3.7-fold, respectively) as well as a 
25 % reduction in RBCs in BMAC following vertical 
centrifugation. The platelet enrichment is highly 
valued as these cells contain various growth factors 
that could enhance osteogenesis, chondrogenesis 
and angiogenesis during repair (Altaie et al., 2016; 
Cassano et al., 2018). Furthermore, PRP and BMAC are 
increasingly investigated in the laboratory or clinical 
settings as a combined product for regenerative 
therapies, particularly for bone repair (Betsch et 
al., 2013; Lee et al., 2014; Smyth et al., 2012). The 
enrichment in WBCs could be of value in regenerative 
therapies as MSC and WBC interactions have been 
shown to be involved in bone and other tissue healing 
(El-Jawhari et al., 2016). Also, an interesting positive 
correlation between MSC and WBC enrichment 
was found, probably because MSCs and WBCs 
were co-isolated in the buffy coat layer following 
processing. Further investigations of the biological 
significance of WBCs in BMAC preparation for 
tissue repair and how this effect could be correlated 
with clinical efficacy of treatment are needed. A 
positive and significant correlation between high 
cellularity of BMA (particularly platelets and RBCs) 
and MSC enrichment was additionally noted. This 
finding could indicate that the larger the BMA cell 
number, the more efficient is the BM concentration. 
This observation agreed with a previous report 
indicating that the cellularity of a buffy coat collected 
by BM centrifugation correlates well with original 
BM cellularity (Chang et al., 2010). Also, the present 
study finding could suggest a probable risk of a 
reduced MSC yield after concentration in conditions 
associated with decrease BM cellularity, e.g. ageing.
 BM processing by vertical centrifugation may 
reduce cell viability or increase stress levels in these 
cells (Takeshima et al., 2017). However, the viability 
of BMAC-MSCs was maintained after vertical 
centrifugation. In agreement, a recent study reported 
that cell viability is nearly 90 % after processing of 
BMA by two other concentration systems, Emcyte 
GenesisCS® and Harvest-Tech devices (Schafer 
et al., 2019). Interestingly, ROS levels were found 
to be reduced in BMAC processed by vertical 
centrifugation when compared to BMA. These data 
may indicate a cellular response to low oxygen 
during processing since hypoxia can reduce ROS 
levels (Kucera et al., 2017). Additionally, ROS levels 
have been suggested to have a regulating functions in 
normal cell responses (i.e. redox biology) rather than 
being linked to cell damage (Schieber and Chandel, 
2014). Despite the noted reduction in ROS levels 
following processing by vertical centrifugation, using 
semi-quantitative assay (colony integrated density), 
native BMAC-MSCs were able to form colonies with 
similar proliferative potential to the donor-matched 
unprocessed BMA-MSCs.
 In addition to the quantity, the quality of BMAC-
MSCs is also important to consider when assessing 
the effectiveness of BM concentration systems. For 
BioCUE™, BMAC-MSCs isolated using this system 
have competent CFU-F formation as well as ALP 
expression in osteogenic medium (Hakimi et al., 
2014; Woodell-May et al., 2015). Additionally, an 
in vivo study has proven the osteogenic capacity of 
these cells (Hakimi et al., 2014). Moreover, BMAC-
MSCs from samples processed by SmartPReP-2® 
effectively secrete angiogenic factors and express 
ALP, indicating preserved osteogenic capability 
(Jager et al., 2011; Schafer et al., 2019). Uniquely, 
the in vitro assays performed in the present study 
aimed to assess the differentiation capabilities of 
BMAC-MSCs derived from vertical-centrifugation-
processed samples as compared to those of donor-
matched unprocessed BMA samples. Using both 
qualitative and quantitative methods, the present 
study showed for the first time that human culture-
expanded BMAC-MSCs from vertical centrifugation 
displayed active osteogenesis, chondrogenesis and 
adipogenesis. The secretion of immunomodulatory 
and vascular mediators by these BMAC-MSCs 
appeared intact, as indicated by the soluble factor 
levels in cultures and their gene expression levels. 
The angiogenic functions of MSCs are mainly 
related to VEGF, which modulates migration and 
mitosis of endothelial cells, thus helping to initiate 
angiogenesis in response to tissue injuries (Ferrara 
and Gerber, 2001; Holmes et al., 2007). Additionally, 
immunomodulatory mediators such as TGFβ and 
PGE2 have been linked to the role of MSCs in 
controlling inflammation associated with tissue 
damage, which could help the progress of tissue 
repair, particularly bone and cartilage (El-Jawhari et 
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al., 2016). Although no functional assays for Heragen® 
maxx-processed BMAC cells were performed, the 
present study assessed, for the first time, the secretion 
of these angiogenic and immunomodulatory factors 
by MSCs processed by vertical centrifugation. A 
previous study has shown that the total levels of 
soluble factors such as platelet-derived growth 
factor-BB, VEGF, macrophage colony-stimulating 
factor and interleukin-1 are preserved following 
BM concentration using horizontal systems such as 
SmartPReP-2® (Schafer et al., 2019).
 The preserved differentiation functionality and 
angiogenic potential of BMAC-MSCs processed 
by vertical centrifugation indicated their high 
potential value for mesenchymal tissue regeneration. 
Concentrated BM-MSCs have promising reparative 
effects in various pathological conditions, such as 
degenerative osteochondral lesions, osteoarthritis-
associated cartilage loss and bone fractures. Both 
animal studies and human clinical trials have 
reported positive results for BMAC application in 
bone and cartilage healing (Connolly et al., 1989; 
Zhong et al., 2012). Also, Gobbi et al. (2011; 2015) 
demonstrated that patients with large patellofemoral 
chondral lesions show significantly improved clinical 
outcomes after autologous application with BMAC 
gained by Harvest-Tech systems, with no adverse 
effects. Furthermore, conventional centrifugation 
yielding BMAC is valuable to treat atrophic non-union 
of tibial fractures (Hernigou et al., 2005a; 2005b). With 
regards to vertical centrifugation, Douras et al. (2018) 
have recently reported successful healing of a medial 
malleus non-union fracture case using this system. 
In this case report, an application of BMAC together 
with a BMP-2 sponge and iliac crest autologous graft, 
according to the elements of ‘diamond concept’ for 
bone regeneration (Giannoudis et al., 2007), was 
associated with a gradual integration of the bone 
graft implanted and a complete osseous healing 
at the 6 months follow up (Douras et al., 2018). In 
addition to regeneration, BMAC-MSCs processed by 
vertical centrifugation could maintain the production 
of immunomodulatory factors; thus, these cells can 
be potentially valuable in treating inflammatory/
autoimmune-based conditions. Examples of MSC 
application due to their immunomodulatory capacity 
include graft-versus-host disease, asthma, ulcerative 
colitis, multiple sclerosis and systemic lupus 
erythematosus (Gao et al., 2016). More studies would 
be needed to assess the efficacy of BMAC produced 
by vertical centrifugation in various regenerative and 
inflammatory conditions and within large cohorts of 
patients.
 Different surface markers including CD271 have 
been proposed to characterise BM-MSCs (Boxall 
and Jones, 2012; 2015). Furthermore, BM-MSCs have 
also been suggested to contain different subsets of 
cells according to the expression of other surface 
markers (Elahi et al., 2016). This heterogeneity of 
BM-MSC phenotypes may as well be exacerbated by 
the donor to donor variation. One limitation of the 
present study could be that the biology of native BM-
MSCs was assessed as CD45low CD271high; however, 
this population is considered to be a surrogate 
population of BM-MSCs (El-Jawhari et al., 2017). 
Furthermore, CFU-F assays was also used in addition 
to the validated flow cytometry phenotype and both 
methods consistently showed enrichment of MSCs 
and maintenance of their survival and proliferative 
capacities. It would be interesting in future work to 
use antibodies from different suppliers to characterise 
the MSC populations. For differentiation assays and 
soluble mediator levels, culture-expanded MSCs, 
as standardly defined in vitro, were used (Dominici 
et al., 2006) to gain adequate numbers of these cells 
for these functional assays. The osteogenesis and 
adipogenesis assay outcomes were also normalised to 
cell counts. Although the GAG assay was performed 
without cell normalisation, the chondrogenic marker 
expression was quantitively measured relative to a 
housekeeping gene to show the cellular levels. Future 
testing of a wider range of tri-lineage markers and 
assays would aid interpretation of the MSC fractions 
isolated. Another limitation of the study was that it 
only analysed the regenerative capacity of BMAC-
derived cells in vitro, and future in vivo studies will 
be interesting to confirm the value of such BM-
concentrating system.
Conclusions
The process of centrifugation-based BM concentration 
helps to enrich MSCs in a small volume of BMAC, 
which is valuable for small sized bone defects and 
loading scaffolds or membranes used for various 
bone/cartilage regenerative therapies. Other methods 
for separating or enriching BM-MSCs, such as 
antibody-biding methods, FACS and MACS are also 
potentially useful (Tomlinson et al., 2013). However, 
compared to centrifugation systems, these antibody-
based techniques need more time and include extra 
manipulation steps with the use of chemical reagents. 
Of note, applying recommended BM aspiration 
techniques, such as using small syringes for collection 
and multiple aspirates, could be essential to avoid 
the dilution of BMA samples and to improve the 
yield of BM-MSCs regardless of the enrichment 
method (Hernigou et al., 2013). The tested vertical 
centrifugation system for BM concentration was 
as effective in enriching MSCs in a small volume 
and more importantly in a much shorter time than 
conventional horizontal centrifugation systems. 
Additionally, this vertical centrifugation system 
has other more practical advantages, including 
the compact size of the instrument and the ease to 
collect BMAC layer as well as discard plasma and 
many RBCs. A limitation of the study was that the 
functionality of the BMAC-MSCs was not analysed 
across the three BM concentration devices. However, 
vertical centrifugation did not compromise the 
functional potentials of BMAC-MSCs as compared to 
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donor-matched unprocessed BMA-MSCs. The vertical 
centrifugation system helped also to enrich platelets, 
which have great potential to enhance bone and 
cartilage regeneration. Such a fast BM concentration 
system could potentially be a helpful tool to optimise 
successful bone and cartilage regenerative therapies. 
For future work, it will be interesting to assess the 
in vivo functions of these BMAC-MSCs in animal 
models after using the vertical centrifugation 
system in comparison to the other BM concentration 
methods. Such investigation would aid determination 
of the effectiveness of these BM systems for wider 
research application. Moreover, it would be valuable 
to investigate if and how the numbers of applied 
MSCs together with other BMAC cells (e.g. WBCs 
and platelets) are correlated with improved clinical 
efficacy for different tissue regenerative applications.
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Discussion with Reviewer
Reviewer: The manuscript reported on a vertical 
centrifugation system resulting in 4-fold enrichment 
in multipotent stromal cells. At the same time, data 
also suggested enrichment of platelets and leukocytes. 
Could the authors speculate which influence this 
might have on the regenerative potential of the BM 
concentrate when directly applied to a defect site in 
an intra-operative setting?
Authors: The enriched MSCs and platelets in BM 
concentrate would be of great potential value for the 
healing of the bone/cartilage defect. The enriched 
MSCs would have an increased osteogenic and 
chondrogenic effect. Additionally, enriched platelets 
release more of the growth factors supporting the 
proliferation and survival of MSCs and enhancing 
their reparatory impact. The leucocytes present 
in PRP preparations did not seem to change the 
proliferation or migration of MSCs, as reported 
before (Moisley et al., 2019, additional reference). 
However, the outcome of the enriched leukocytes 
in BM concentrate on the healing process would 
require further investigations. This cell cocktail of 
BM concentrate has the advantages of being quickly 
processed within theatre time and being autologous, 
with no expected immunogenic adverse effects.
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proliferation and migration of mesenchymal stem 
cells using platelet products: A rational approach to 
bone regeneration. J Orthop Res 37: 1329-1338.
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